Safety assessment
In total, 142 (77 Cohort 1 and 65 Cohort 2) patients were assessed for
AEs (Table S2 ). Most AEs were mild (≤ grade 2), treatable, and
reversible. Commonly observed AEs ≥ grade 3 included neutropenia (n=44,
31.0%), febrile neutropenia (n=12, 8.4%), anaemia (n=6, 4.2%),
diarrhoea (n=2, 1.4%), and anorexia (n=1, 0.7%). BEV-associated AEs
were not observed. All cases of non-CNS bleeding (n=26, 3.5%),
hypertension (n=21, 14.8%), proteinuria (n=13, 9.2%), or venous
thromboembolic events (n=3, 2.1%) were rare and treatable in patients
with or without prior BEV use.